Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 353 of 1,261
  1. US 10975388

    Methods and compositions for nucleic acid and protein payload delivery

    LIGANDAL, INC. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  2. US 10973830

    Substituted quinoxaline DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  3. US 10975064

    RIP1 inhibitory compounds and methods for making and using the same

    Rigel Pharmaceuticals, Inc. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  4. CN 112638413

    Oral immunotherapy unit dose dispensing systems and methods

    ALLERGEN RES CORPORATION · Granted Apr 9, 2021 · Expires Apr 4, 2041

    granted
  5. WO 2021064188

    COMBINAISON COMPRENANT UN INHIBITEUR DE HDAC, UN INHIBITEUR DE CTLA-4 ET UN INHIBITEUR DE PD-1 OU UN INHIBITEUR DE PD-L1 POUR LE TRAITEMENT DU CANCER

    4SC AG [DE] · Granted Apr 8, 2021 · Expires Apr 3, 2041

    granted
  6. US 10968495

    Lactobacillus reuteri and use thereof

    INFINITUS (CHINA) COMPANY LTD. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  7. US 10967063

    Surfactant-free, water-free formable composition and breakable foams and their uses

    Vyne Therapeutics Inc. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  8. US 10968205

    Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  9. US 10968249

    Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

    Enanta Pharmaceuticals, Inc. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  10. US 10967016

    Traditional Chinese medicine composition and use thereof

    INFINITUS (CHINA) COMPANY LTD. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  11. US 10966931

    Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances

    Jazz Pharmaceuticals, Inc. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  12. US 10967050

    Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

    Rani Therapeutics, LLC · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  13. US 10966970

    Fused tricyclic compounds and uses thereof in medicine

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  14. US 10967051

    Methods and compositions for treating NAFLD, hepatic steatosis, and sequelae thereof

    Oramed Ltd. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  15. US 10968442

    Chimeric clotting factors

    BIOVERATIV THERAPEUTICS INC. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  16. US 10968261

    Methods and compositions for genome engineering

    Sangamo Therapeutics, Inc. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  17. US 10968278

    Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  18. US 10968248

    Trinucleotide mRNA cap analogs

    Arcturus, Inc. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  19. US 10968452

    Polynucleotide agents targeting aminolevulinic acid synthase-1 (ALAS1) and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  20. US 10968231

    Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders

    Takeda Pharmaceutical Company Limited · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  21. US 10968222

    2-azabicyclo hexane JAK inhibitor compound

    Theravance Biopharma R&D IP, LLC · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  22. US 10968213

    Cyclopropanamine compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  23. US 10968201

    Bicyclic carboxamides and methods of use thereof

    TEMPEST THERAPEUTICS, INC. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  24. US 10968206

    Cannabinergic nitrate esters and related analogs

    Northwestern University · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.